| human | Q5 |
| P973 | described at URL | https://cdc.confex.com/cdc/std2008/webprogram/Person10599.html |
| P6178 | Dimensions author ID | 01066145734.00 |
| P227 | GND ID | 1107563755 |
| P213 | ISNI | 0000000027594575 |
| P244 | Library of Congress authority ID | n86062966 |
| P1207 | NUKAT ID | n2020069580 |
| P214 | VIAF ID | 70409222 |
| P27 | country of citizenship | United States of America | Q30 |
| P734 | family name | Markowitz | Q21487975 |
| Markowitz | Q21487975 | ||
| Markowitz | Q21487975 | ||
| P735 | given name | Lauri | Q127165196 |
| Lauri | Q127165196 | ||
| P106 | occupation | medical researcher | Q15401884 |
| P21 | sex or gender | female | Q6581072 |
| Q37847428 | "Testing-only" visits: an assessment of missed diagnoses in clients attending sexually transmitted disease clinics |
| Q50347345 | 1049Evaluating the Population Impact of HPV Vaccine on High Grade Cervical Intraepithelial Neoplasia Rates in an Era of Decreasing Screening. |
| Q59333696 | 2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017 |
| Q94119716 | 962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016 |
| Q39777165 | A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination |
| Q37850064 | A prospective study of the psychosocial impact of a positive Chlamydia trachomatis laboratory test. |
| Q37315930 | A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. |
| Q34018830 | Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand |
| Q37683941 | Acceptability of human papillomavirus vaccine for males: a review of the literature |
| Q35987591 | Acceptability of school requirements for human papillomavirus vaccine |
| Q44713485 | Acute measles mortality in the United States, 1987-2002. |
| Q83223573 | Adolescent vaccination: recommendations from the National Vaccine Advisory Committee |
| Q30534669 | Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels |
| Q41447116 | Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. |
| Q37802640 | Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. |
| Q64127440 | Assessing neonatal herpes reporting in the United States, 2000-2005 |
| Q37864113 | Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents |
| Q64135840 | Association of Provider Recommendation and Human Papillomavirus Vaccination Initiation among Male Adolescents Aged 13-17 Years-United States |
| Q46608592 | Availability of human papillomavirus vaccine at medical practices in an area with elevated rates of cervical cancer |
| Q47100322 | CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide |
| Q42240209 | CDC grand rounds: Reducing the burden of HPV-associated cancer and disease |
| Q36407727 | Can clinical tests help monitor human papillomavirus vaccine impact? |
| Q47189724 | Cervical Adenocarcinoma in Situ in the United States: Results from Population-based Laboratory Surveillance, 2008–2014. |
| Q93070130 | Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015 |
| Q45954720 | Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ: comparison of ICD-9 codes and pathology results--Kaiser Permanente, United States, 2000-2005. |
| Q34073427 | Cervical specimen order and performance measures of Chlamydia trachomatis diagnostic testing |
| Q45213820 | Challenges in congenital syphilis surveillance: how are congenital syphilis investigations classified? |
| Q36584400 | Chapter 27: Research needs following initial licensure of virus-like particle HPV vaccines |
| Q37850177 | Chlamydia partner services for females in California family planning clinics |
| Q37135216 | Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls |
| Q40656135 | Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis |
| Q34974306 | Comparison of methods for detection of Chlamydia trachomatis and Neisseria gonorrhoeae using commercially available nucleic acid amplification tests and a liquid pap smear medium |
| Q47708282 | Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. |
| Q64126967 | Compliance with recommended dosing intervals for HPV vaccination among females, 13-17 years, National Immunization Survey-Teen, 2008-2009 |
| Q33772648 | Comprehensive control of human papillomavirus infections and related diseases |
| Q51856187 | Comprehensive control of human papillomavirus infections and related diseases. |
| Q53078836 | Comprehensive control of human papillomavirus infections and related diseases. |
| Q40201045 | Concordance Between Anal and Oral Human Papillomavirus Infections Among Young Men Who have Sex With Men. |
| Q37833288 | Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States |
| Q36707185 | Contact-tracing outcomes among male syphilis patients in Fulton County, Georgia, 2003. |
| Q37009015 | Cost-effectiveness of human papillomavirus vaccination in the United States |
| Q64137462 | Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States |
| Q92499094 | Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination |
| Q90082647 | Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey |
| Q64126268 | Delay and refusal of human papillomavirus vaccine for girls, national immunization survey-teen, 2010 |
| Q92849745 | Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity |
| Q35627542 | Developments in the screening for Chlamydia trachomatis: a review |
| Q89259166 | Disclosure of Sexual Behavior Is Significantly Associated With Receiving a Panel of Health Care Services Recommended for Men Who Have Sex With Men |
| Q37246616 | Early Syphilis Among Men Who Have Sex with Men in the US Pacific Northwest, 2008-2013: Clinical Management and Implications for Prevention |
| Q37291444 | Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia |
| Q37862926 | Effect of specimen order on Chlamydia trachomatis and Neisseria gonorrhoeae test performance and adequacy of Papanicolaou smear |
| Q91805518 | Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States |
| Q91078164 | Effectiveness of 1, 2, AND 3 Human Papillomavirus Vaccine doses against HPV-16/18 positive High-grade Cervical Lesions |
| Q39672720 | Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population |
| Q64100865 | Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016 |
| Q44714591 | Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. |
| Q42286605 | Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. |
| Q45734478 | Evaluation of Syracuse Healthy Start’s Program for Abnormal Flora Management to Reduce Preterm Birth Among Pregnant Women |
| Q38228363 | Evaluation of a surveillance case definition for anogenital warts, Kaiser Permanente northwest |
| Q42281960 | Evaluation of genital self-sampling methods for HPV detection in males |
| Q46468308 | Evaluation of syphilis reactor grids: optimizing impact |
| Q35541981 | Evaluation of the Determine Rapid Syphilis TP assay using sera |
| Q37845713 | Expedited partner therapy in federally qualified health centers--New York City, 2012. |
| Q45742099 | Factors associated with human papillomavirus vaccination among young adult women in the United States. |
| Q64130358 | Genital human papillomavirus infection |
| Q34764180 | Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999--2004. |
| Q37835382 | Genotype-Specific Concordance of Chlamydia trachomatis Genital Infection Within Heterosexual Partnerships |
| Q57870951 | HIV genital shedding and safety of Carraguard use by HIV-infected women: a crossover trial in Thailand |
| Q39903046 | HPV 6/11, 16, 18 seroprevalence in men in two US cities. |
| Q90131809 | HPV Vaccine Delivery Practices by Primary Care Physicians |
| Q37120555 | HPV genotypes detected in cervical cancers from Alaska Native women, 1980-2007. |
| Q28730863 | HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006 |
| Q38389195 | HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States |
| Q40135675 | HPV vaccination of boys in primary care practices |
| Q36368353 | HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011 |
| Q45951531 | HPV vaccine implementation in STD clinics--STD Surveillance Network. |
| Q80796534 | HPV vaccines prophylactic, not therapeutic |
| Q40464632 | Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. |
| Q36380403 | Health care use and opportunities for human papillomavirus vaccination among young men who have sex with men. |
| Q61161028 | Human Papillomavirus (HPV) 6, 11, 16, and 18 Prevalence Among Females in the United States—National Health and Nutrition Examination Survey, 2003–2006: Opportunity to Measure HPV Vaccine Impact? |
| Q61161006 | Human Papillomavirus Genotypes in High-Grade Cervical Lesions in the United States |
| Q40162071 | Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men and Transgender Women in 2 US Cities, 2012-2014. |
| Q51549420 | Human Papillomavirus Vaccination Practices: A Survey of US Physicians 18 Months After Licensure |
| Q37689280 | Human Papillomavirus Vaccination and Age at First Sexual Activity, National Health and Nutrition Examination Survey. |
| Q92637971 | Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices |
| Q91560556 | Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses |
| Q60501000 | Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States |
| Q64124218 | Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States |
| Q39624501 | Human Papillomavirus-Associated Cancers - United States, 2008-2012. |
| Q92772435 | Human Papillomavirus-Attributable Cancers - United States, 2012-2016 |
| Q34777995 | Human papilloma virions in the laboratory |
| Q43606754 | Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. |
| Q80428065 | Human papillomavirus prevalence and type distribution in male anogenital sites and semen |
| Q45375225 | Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States |
| Q54236736 | Human papillomavirus vaccination coverage among females and males, National Health and Nutrition Examination Survey, United States, 2007-2016. |
| Q47777631 | Human papillomavirus vaccination coverage using two-dose or three-dose schedule criteria. |
| Q83484020 | Human papillomavirus vaccination history among women with precancerous cervical lesions: disparities and barriers |
| Q54219037 | Human papillomavirus vaccination in commercially-insured vaccine-eligible males and females, United States, 2007-2014. |
| Q43455447 | Human papillomavirus vaccination series initiation and completion, 2008-2009. |
| Q42196803 | Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). |
| Q55055392 | Human papillomavirus vaccine and sexual behavior among adolescent and young women. |
| Q64129516 | Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007–2008 |
| Q57170683 | Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs |
| Q45940652 | Human papillomavirus vaccine initiation among adolescent girls in high-risk communities. |
| Q64132057 | Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer |
| Q38064062 | Human papillomavirus vaccine introduction--the first five years |
| Q36871974 | Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine |
| Q61161009 | Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions |
| Q43284143 | Improvement in healing and reduction in HIV shedding with episodic acyclovir therapy as part of syndromic management among men: a randomized, controlled trial |
| Q42275265 | Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations |
| Q37140541 | Incidence of neonatal herpes simplex virus infections in two managed care organizations: implications for surveillance. |
| Q37857171 | Increase in sexual risk behavior and prevalence of Chlamydia trachomatis among adolescents in Northern Thailand |
| Q41919217 | Increases in Ocular Syphilis-North Carolina, 2014-2015. |
| Q40163773 | Increasing Human Papillomavirus Vaccine Coverage Among Men Who Have Sex With Men-National HIV Behavioral Surveillance, United States, 2014. |
| Q64133752 | Increasing human papillomavirus vaccination at the recommended age |
| Q30734350 | Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data |
| Q43893716 | Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty |
| Q37689161 | Invasive and in situ cervical cancer reported to the vaccine adverse event reporting system (VAERS). |
| Q36172432 | Investigation of metronidazole use during pregnancy and adverse birth outcomes |
| Q36318591 | Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003-2010. |
| Q34512122 | Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area |
| Q64126788 | Maternal underestimation of child's sexual experience: suggested implications for HPV vaccine uptake at recommended ages |
| Q31133268 | Measuring Adolescent Human Papillomavirus Vaccine Coverage: A Match of Sexually Transmitted Disease Clinic and Immunization Registry Data |
| Q43062162 | Men who have sex with men in the United States: demographic and behavioral characteristics and prevalence of HIV and HSV-2 infection: results from National Health and Nutrition Examination Survey 2001-2006. |
| Q37028689 | Minor consent and delivery of adolescent vaccines |
| Q86592133 | Missed opportunities for preventing congenital syphilis infection |
| Q39599027 | Molecular Typing of Treponema pallidum in Ocular Syphilis |
| Q34041487 | Molecular subtyping of Treponema pallidum from North and South Carolina |
| Q35997434 | Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012. |
| Q85245816 | Monitoring HPV vaccine impact: early results and ongoing challenges |
| Q40703383 | Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Men-United States, 2012-2014. |
| Q50091385 | Monitoring the impact of HPV vaccine in males-Considerations and challenges |
| Q33633353 | Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors |
| Q40678763 | National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2014 |
| Q39454056 | National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2015 |
| Q38610144 | National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2016 |
| Q58709271 | National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017 |
| Q92772450 | National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2018 |
| Q44648379 | New, and some not-so-new, vaccines for adolescents and diseases they prevent |
| Q42238871 | Noninfluenza vaccination coverage among adults - United States, 2012. |
| Q33827024 | Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections |
| Q37156922 | Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae oropharyngeal infections |
| Q39217522 | Ocular Syphilis - Eight Jurisdictions, United States, 2014-2015. |
| Q46314400 | Parent attitudes about school requirements for human papillomavirus vaccine in high-risk communities of Los Angeles, California |
| Q37870474 | Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial |
| Q64128441 | Persons with early syphilis identified through blood or plasma donation screening in the United States |
| Q38164983 | Population impact of HPV vaccines: summary of early evidence |
| Q37288157 | Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes |
| Q37834117 | Population-attributable fraction of tubal factor infertility associated with chlamydia |
| Q40812471 | Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States |
| Q28084924 | Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis |
| Q37699644 | Post-licensure monitoring of HPV vaccine in the United States |
| Q52687082 | Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. |
| Q42200976 | Postlicensure monitoring of HPV vaccination programmes |
| Q28255537 | Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine |
| Q64132179 | Pre-treatment syphilis titers: distribution and evaluation of their use to distinguish early from late latent syphilis and to prioritize contact investigations |
| Q38460201 | Present status of human papillomavirus vaccine development and implementation |
| Q42218612 | Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the U.S.A., National Health and Nutrition Examination Surveys, 2003-2006. |
| Q40539247 | Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003-2006. |
| Q38974297 | Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014. |
| Q40780056 | Prevalence of HPV After Introduction of the Vaccination Program in the United States. |
| Q38809406 | Prevalence of HPV in Adults Aged 18-69: United States, 2011-2014. |
| Q28290509 | Prevalence of HPV infection among females in the United States |
| Q34567930 | Prevalence of HPV infection among men: A systematic review of the literature. |
| Q45077291 | Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact |
| Q41933605 | Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014. |
| Q34007201 | Prevalence of cervical and oral human papillomavirus infections among US women |
| Q42275270 | Prevalence of circumcision among men and boys aged 14 to 59 years in the United States, National Health and Nutrition Examination Surveys 2005-2010. |
| Q34003387 | Prevalence of circumcision and herpes simplex virus type 2 infection in men in the United States: the National Health and Nutrition Examination Survey (NHANES), 1999-2004. |
| Q45251131 | Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. |
| Q47558910 | Prevalence of genital human papillomavirus among sexually experienced males and females aged 14-59 years, United States, 2013-2014. |
| Q37854000 | Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States |
| Q31150255 | Prevalence of syphilis seroreactivity in the United States: data from the National Health and Nutrition Examination Surveys (NHANES) 2001-2004. |
| Q53959654 | Preventing vaccine-preventable diseases in low-resource communities. |
| Q39135541 | Primary Care Physicians' Perspectives About HPV Vaccine |
| Q61161051 | Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges |
| Q91814501 | Primary care physician support for harmonizing HPV vaccination recommendations across genders - United States, 2018 |
| Q24202048 | Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors |
| Q24235373 | Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors |
| Q45393816 | Provider perceptions of barriers and facilitators of HPV vaccination in a high-risk community |
| Q33166996 | Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States |
| Q28294460 | Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP) |
| Q37014050 | Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines |
| Q37857365 | Rate and predictors of repeat Chlamydia trachomatis infection among men. |
| Q38387890 | Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. |
| Q37840047 | Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. |
| Q51871950 | Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. |
| Q43948948 | Reply to Groner et al and Pei et al. |
| Q43176363 | Response to Pendleton et al. regarding reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States |
| Q37425035 | Risk factors for anogenital human papillomavirus infection in men. |
| Q52602704 | Risk factors for oral HPV infection among young men who have sex with men - 2 cities, United States, 2012-2014. |
| Q37869728 | Risk factors for sexually transmitted diseases in northern Thai adolescents: an audio-computer-assisted self-interview with noninvasive specimen collection |
| Q37870879 | Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections--2002. |
| Q37649854 | Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding |
| Q61161058 | Seroepidemiology of Human Papillomavirus Type 11 in the United States: Results From the Third National Health and Nutrition Examination Survey, 1991–1994 |
| Q45733066 | Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. |
| Q40593521 | Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005-2006. |
| Q59349344 | Seroprevalence of Herpes Simplex Virus Types 1 and 2 Among Pregnant Women and Sexually Active, Nonpregnant Women in the United States |
| Q45399974 | Seroprevalence of herpes simplex virus type 1 in children in the United States |
| Q34604669 | Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States |
| Q42261512 | Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. |
| Q64135508 | Seroprevalence of human papillomavirus 6/11/16/18 among self-identified gay/bisexual men who have sex with men, men who have sex with women, and females, United States, 2003-2010 |
| Q39715651 | Seroprevalence of human papillomavirus type 16 in children |
| Q50179188 | Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. |
| Q37854597 | Sexual and reproductive health of persons aged 10-24 years - United States, 2002-2007. |
| Q37865118 | Sexually transmitted disease services at US colleges and universities. |
| Q46454455 | Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand |
| Q40024765 | Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014. |
| Q38804622 | Surveillance of Vaccination Coverage among Adult Populations - United States, 2015. |
| Q40541126 | Syphilis outbreak among Hispanic immigrants in Decatur, Alabama: association with commercial sex. |
| Q38177539 | Systematic review of human papillomavirus vaccine coadministration |
| Q38823050 | TPrevalence of HPV in Adults Aged 18-69: United States, 2011-2014. |
| Q92276222 | Temporal Trends in the Incidence of Anogenital Warts: Impact of Human Papillomavirus Vaccination |
| Q52675289 | Ten Years of Human Papillomavirus Vaccination in the United States. |
| Q43697958 | The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions |
| Q33976365 | The connection between human papillomavirus and oropharyngeal squamous cell carcinomas in the United States: implications for dentistry |
| Q64125374 | The cost-effectiveness of human papillomavirus vaccine catch-up programs for women |
| Q48617316 | The cost-effectiveness of male HPV vaccination in the United States |
| Q37864695 | The effect of correct and consistent condom use on chlamydial and gonococcal infection among urban adolescents |
| Q44741869 | The emergence of Neisseria gonorrhoeae with decreased susceptibility to Azithromycin in Kansas City, Missouri, 1999 to 2000. |
| Q41709029 | The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States. |
| Q41709023 | The estimated lifetime probability of acquiring human papillomavirus in the United States. |
| Q37135272 | The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model |
| Q79960584 | The natural history of HIV-1 infection in young Thai men after seroconversion |
| Q34705454 | The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study |
| Q43484985 | The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination |
| Q51109089 | The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. |
| Q51746905 | The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. |
| Q92974451 | The science of vaccine safety: Summary of meeting at Wellcome Trust |
| Q64134275 | The syphilis reactor grid: help or hindrance for syphilis surveillance? |
| Q37135005 | Timing of HPV vaccine intervals among United States teens with consideration to the current ACIP schedule and the WHO 2-dose schedule |
| Q48473404 | Toward optimal health: a review of vaccine recommendations for women. Interview by Jodi R Godfrey |
| Q90092354 | Transgender Women Have Higher Human Papillomavirus Prevalence Than Men Who Have Sex With Men-Two U.S. Cities, 2012-2014 |
| Q41600830 | Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States. |
| Q64137692 | Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era |
| Q64136607 | Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015 |
| Q64129304 | Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014 |
| Q58709291 | Trends in Human Papillomavirus-Associated Cancers - United States, 1999-2015 |
| Q64060876 | Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006-2014: The impact of human papillomavirus vaccination |
| Q34559709 | Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States |
| Q90989041 | Trends in human papillomavirus (HPV) vaccination initiation among adolescents aged 13-17 by metropolitan statistical area (MSA) status, National Immunization Survey - Teen, 2013 - 2017 |
| Q34471101 | Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001. |
| Q42263501 | Trends in seroprevalence of herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 49 years--United States, 1988 to 2010. |
| Q43115426 | Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population |
| Q43171949 | Two vs Three Doses of Human Papillomavirus Vaccine: New Policy for the Second Decade of the Vaccination Program |
| Q64124111 | Updated medical care cost estimates for HPV-associated cancers: implications for cost-effectiveness analyses of HPV vaccination in the United States |
| Q34073557 | Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines |
| Q30399506 | Uptake of 2009 H1N1 vaccine among adolescent females |
| Q36121464 | Uptake of human papillomavirus vaccine among adolescent males and females: Immunization Information System sentinel sites, 2009-2012. |
| Q41156019 | Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices |
| Q95784494 | Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices |
| Q37850545 | Use of home-obtained vaginal swabs to facilitate rescreening for Chlamydia trachomatis infections: two randomized controlled trials |
| Q41474917 | Vaccination coverage among adults, excluding influenza vaccination - United States, 2013. |
| Q96172173 | Vaccine effectiveness on DNA prevalence of human papillomavirus infection in anal and oral specimens from men who have sex with men- United States, 2016-2018 |
| Q45375449 | Women who have sex with women in the United States: prevalence, sexual behavior and prevalence of herpes simplex virus type 2 infection-results from national health and nutrition examination survey 2001-2006. |
| Q42249868 | Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005. |
Search more.